Thursday, October 4, 2018

Arrowhead Lands $3.7 Billion Licensing Deal With Janssen

Pasadena-based Arrowhead Pharmaceuticals, which develops RNA-based gene therapeutics, has entered into a $3.7 billion license and collaboration agreement with Janssen Pharmaceuticals, the company announced this morning. According to Arrowhead, it will receive $250M in initial funding, comprised of $175M in an upfront payment from Janssen and a $75M equity investment from Johnson & Johnson Innovation, HHDC, with the potential for an additional $3.5 billion in potential milestone payments and future royalties. Arrowhead said the deal includes a research collaboration and option agreement with Janssen, to potentially collaborate for up to three additional RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.